SUSAN BLANEY to Antibodies, Monoclonal
This is a "connection" page, showing publications SUSAN BLANEY has written about Antibodies, Monoclonal.
Connection Strength
1.295
-
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015 Apr 01; 21(7):1558-65.
Score: 0.313
-
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4.
Score: 0.313
-
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6.
Score: 0.287
-
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62.
Score: 0.255
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
Score: 0.049
-
New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep; 24(5):528-34.
Score: 0.044
-
Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9.
Score: 0.021
-
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008 Aug 01; 26(22):3756-62.
Score: 0.013